设计和构建溶瘤病毒。
Designing and building oncolytic viruses.
作者信息
Maroun Justin, Muñoz-Alía Miguel, Ammayappan Arun, Schulze Autumn, Peng Kah-Whye, Russell Stephen
机构信息
Department of Molecular Medicine, Mayo Clinic College of Medicine, Rochester, MN 55905, USA.
出版信息
Future Virol. 2017 Apr;12(4):193-213. doi: 10.2217/fvl-2016-0129. Epub 2017 Mar 31.
Abstract
Oncolytic viruses (OVs) are engineered and/or evolved to propagate selectively in cancerous tissues. They have a dual mechanism of action; direct killing of infected cancer cells cross-primes anticancer immunity to boost the killing of uninfected cancer cells. The goal of the field is to develop OVs that are easily manufactured, efficiently delivered to disseminated sites of cancer growth, undergo rapid intratumoral spread, selectively kill tumor cells, cause no collateral damage and pose no risk of transmission in the population. Here we discuss the many virus engineering strategies that are being pursued to optimize delivery, intratumoral spread and safety of OVs derived from different virus families. With continued progress, OVs have the potential to transform the paradigm of cancer care.
摘要
溶瘤病毒（OVs）经过改造和/或进化，使其能够在癌组织中选择性增殖。它们具有双重作用机制；直接杀死被感染的癌细胞可交叉启动抗癌免疫反应，以增强对未感染癌细胞的杀伤作用。该领域的目标是开发易于生产、能有效递送至癌症扩散生长部位、在肿瘤内快速传播、选择性杀死肿瘤细胞、不造成附带损害且无人群传播风险的溶瘤病毒。在此，我们讨论了为优化源自不同病毒家族的溶瘤病毒的递送、肿瘤内传播和安全性而采用的多种病毒工程策略。随着不断取得进展，溶瘤病毒有可能改变癌症治疗模式。
相似文献
1
Designing and building oncolytic viruses.设计和构建溶瘤病毒。
Future Virol. 2017 Apr;12(4):193-213. doi: 10.2217/fvl-2016-0129. Epub 2017 Mar 31.
2
Oncolytic virotherapy evolved into the fourth generation as tumor immunotherapy.溶瘤病毒治疗已发展为肿瘤免疫治疗的第四代。
J Transl Med. 2023 Jul 25;21(1):500. doi: 10.1186/s12967-023-04360-8.
3
Oncolytic ImmunoViroTherapy: A long history of crosstalk between viruses and immune system for cancer treatment.溶瘤免疫病毒治疗：病毒与免疫系统在癌症治疗中的长期相互作用。
Pharmacol Ther. 2022 Aug;236:108103. doi: 10.1016/j.pharmthera.2021.108103. Epub 2021 Dec 23.
4
Research Advances of Clinical Application of Oncolytic Viruses in Treatment of Gynecologic Cancers.溶瘤病毒在妇科肿瘤治疗中的临床应用研究进展。
Curr Cancer Drug Targets. 2023;23(7):505-523. doi: 10.2174/1568009623666230221154415.
5
Application of oncolytic virus in tumor therapy.溶瘤病毒在肿瘤治疗中的应用。
J Med Virol. 2023 Apr;95(4):e28729. doi: 10.1002/jmv.28729.
6
Recent advances in targeting cancer stem cells using oncolytic viruses.利用溶瘤病毒靶向肿瘤干细胞的最新进展。
Biotechnol Lett. 2020 Jun;42(6):865-874. doi: 10.1007/s10529-020-02857-6. Epub 2020 Mar 12.
7
Updates to the antitumor mechanism of oncolytic virus.肿瘤溶瘤病毒抗肿瘤机制的研究进展。
Thorac Cancer. 2019 May;10(5):1031-1035. doi: 10.1111/1759-7714.13043. Epub 2019 Mar 22.
8
Oncolytic virotherapy as promising immunotherapy against cancer: mechanisms of resistance to oncolytic viruses.溶瘤病毒治疗作为一种有前途的癌症免疫疗法：溶瘤病毒耐药的机制。
Future Oncol. 2022 Jan;18(2):245-259. doi: 10.2217/fon-2021-0802. Epub 2021 Nov 25.
9
Immunovirotherapy: The role of antibody based therapeutics combination with oncolytic viruses.免疫病毒疗法：抗体药物与溶瘤病毒联合治疗的作用。
Front Immunol. 2022 Oct 13;13:1012806. doi: 10.3389/fimmu.2022.1012806. eCollection 2022.
10
The discovery and development of oncolytic viruses: are they the future of cancer immunotherapy?溶瘤病毒的发现和开发：它们是癌症免疫疗法的未来吗？
Expert Opin Drug Discov. 2021 Apr;16(4):391-410. doi: 10.1080/17460441.2021.1850689. Epub 2020 Dec 14.
引用本文的文献
1
Oncolytic Viruses as a Novel Therapeutic Approach for Colorectal Cancer: Mechanisms, Current Advances, and Future Directions.溶瘤病毒作为一种治疗结直肠癌的新型方法：作用机制、当前进展及未来方向
Cancers (Basel). 2025 May 31;17(11):1854. doi: 10.3390/cancers17111854.
2
Advancing ORFV-Based Therapeutics to the Clinical Stage.将基于羊口疮病毒的疗法推进到临床阶段。
Rev Med Virol. 2025 May;35(3):e70038. doi: 10.1002/rmv.70038.
3
Genetic advancements in breast cancer treatment: a review.乳腺癌治疗中的遗传学进展：综述
Discov Oncol. 2025 Feb 7;16(1):127. doi: 10.1007/s12672-025-01884-x.
4
Cancer-Specific Activation of the Vesicular Stomatitis Virus Matrix by Survivin Promoter in Breast Cancer Cells.生存素启动子在乳腺癌细胞中对水疱性口炎病毒基质蛋白的肿瘤特异性激活作用
Mol Biotechnol. 2025 Jan 17. doi: 10.1007/s12033-024-01359-4.
5
A Phase I Clinical Trial of Intrahepatic Artery Delivery of TG6002 in Combination with Oral 5-Fluorocytosine in Patients with Liver-Dominant Metastatic Colorectal Cancer.肝动脉注射TG6002联合口服5-氟胞嘧啶用于肝转移为主的转移性结直肠癌患者的I期临床试验。
Clin Cancer Res. 2025 Apr 1;31(7):1243-1256. doi: 10.1158/1078-0432.CCR-24-2498.
6
Virus nanotechnology for intratumoural immunotherapy.用于肿瘤内免疫治疗的病毒纳米技术。
Nat Rev Bioeng. 2024 Nov;2(11):916-929. doi: 10.1038/s44222-024-00231-z. Epub 2024 Sep 23.
7
The design and engineering of synthetic genomes.合成基因组的设计与工程
Nat Rev Genet. 2025 May;26(5):298-319. doi: 10.1038/s41576-024-00786-y. Epub 2024 Nov 6.
8
Challenges and strategies toward oncolytic virotherapy for leptomeningeal metastasis.溶瘤病毒治疗脑膜转移的挑战与策略。
J Transl Med. 2024 Nov 5;22(1):1000. doi: 10.1186/s12967-024-05794-4.
9
Translation of oncolytic viruses in sarcoma.溶瘤病毒在肉瘤中的翻译。 （不过这个译文表述不太符合正常语境，推测原文可能有误，或许是“Translation of research on oncolytic viruses in sarcoma.”之类，可译为“肉瘤中溶瘤病毒的研究译文” ） 仅按给定原文准确翻译就是上述内容。
Mol Ther Oncol. 2024 Jun 5;32(3):200822. doi: 10.1016/j.omton.2024.200822. eCollection 2024 Sep 19.
10
Tutorial: design, production and testing of oncolytic viruses for cancer immunotherapy.教程：用于癌症免疫疗法的溶瘤病毒的设计、生产和测试。
Nat Protoc. 2024 Sep;19(9):2540-2570. doi: 10.1038/s41596-024-00985-1. Epub 2024 May 20.
本文引用的文献
1
Into the clinic: Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy.进入临床：替莫唑胺（T-VEC），一种首创的肿瘤内溶瘤病毒治疗药物。
J Immunother Cancer. 2016 Sep 20;4:53. doi: 10.1186/s40425-016-0158-5. eCollection 2016.
2
Safe and Effective Treatment of Experimental Neuroblastoma and Glioblastoma Using Systemically Delivered Triple MicroRNA-Detargeted Oncolytic Semliki Forest Virus.采用系统递送三重 miRNA 靶向溶瘤 Semliki Forest 病毒治疗实验性神经母细胞瘤和神经胶质瘤的安全性和有效性。
Clin Cancer Res. 2017 Mar 15;23(6):1519-1530. doi: 10.1158/1078-0432.CCR-16-0925. Epub 2016 Sep 16.
3
Recombinant mumps virus as a cancer therapeutic agent.重组腮腺炎病毒作为癌症治疗剂。
Mol Ther Oncolytics. 2016 Aug 10;3:16019. doi: 10.1038/mto.2016.19. eCollection 2016.
4
Safety Studies in Tumor and Non-Tumor-Bearing Mice in Support of Clinical Trials Using Oncolytic VSV-IFNβ-NIS.使用溶瘤性水疱性口炎病毒-干扰素β-钠碘同向转运体（VSV-IFNβ-NIS）支持临床试验的肿瘤负荷和非肿瘤负荷小鼠的安全性研究
Hum Gene Ther Clin Dev. 2016 Sep;27(3):111-22. doi: 10.1089/humc.2016.061.
5
Ultrasound-mediated oncolytic virus delivery and uptake for increased therapeutic efficacy: state of art.超声介导的溶瘤病毒递送与摄取以提高治疗效果：现状
Oncolytic Virother. 2015 Nov 25;4:193-205. doi: 10.2147/OV.S66097. eCollection 2015.
6
Advances in the design and development of oncolytic measles viruses.溶瘤麻疹病毒的设计与开发进展
Oncolytic Virother. 2015 Aug 27;4:109-18. doi: 10.2147/OV.S66078. eCollection 2015.
7
Endothelial Progenitor Cells as Shuttle of Anticancer Agents.内皮祖细胞作为抗癌药物的载体
Hum Gene Ther. 2016 Oct;27(10):784-791. doi: 10.1089/hum.2016.066.
8
Improving the safety of T-Cell therapies using an inducible caspase-9 gene.利用可诱导的半胱天冬酶-9基因提高T细胞疗法的安全性。
Exp Hematol. 2016 Nov;44(11):1013-1019. doi: 10.1016/j.exphem.2016.07.011. Epub 2016 Jul 26.
9
Oncolytic Viruses in Cancer Treatment: A Review.溶瘤病毒在癌症治疗中的应用：综述。
JAMA Oncol. 2017 Jun 1;3(6):841-849. doi: 10.1001/jamaoncol.2016.2064.
10
Oncolytic Viruses: Therapeutics With an Identity Crisis.溶瘤病毒：身份危机的疗法
EBioMedicine. 2016 Jul;9:31-36. doi: 10.1016/j.ebiom.2016.06.046. Epub 2016 Jul 2.
Zotero 插件